Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients

Haematologica

Volumn 87, Issue 8, 2002, Pages 816-821

  Zinzani, Pier Luigi ^a   Tani, Monica ^a   Molinari, Anna Lia ^a   Stefoni, Vittorio ^a   Zuffa, Eliana ^a   Alinari, Lapo ^a   Gabriele, Annalisa ^a   Bonifazi, Francesca ^a   Albertini, Patrizia ^a   Salvucci, Marzia ^a   Tura, Sante ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aggressive NHL; HD; IEV regimen; PBSC mobilization; Relapse refractory patients

Indexed keywords

EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; ANTINEOPLASTIC AGENT; IEV PROTOCOL;

ADOLESCENT; ADULT; ALOPECIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; SALVAGE THERAPY; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; DISEASE FREE SURVIVAL; LYMPHOMA; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RECURRENT DISEASE; REMISSION; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EPIRUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMAN; IFOSFAMIDE; LYMPHOMA; LYMPHOMA, HIGH-GRADE; MALE; MIDDLE AGE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; HUMANS; MIDDLE AGED;

EID: 0035986756     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
3. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group
4. Autologous stem cell transplantation as adjuvant treatment vs no further therapy for poorrisk Hodgkin's disease in first complete remission after MOPP/ABVD
5. Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH 87-2 protocol. A GELA study
6. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
7. Chemotherapy of nonHodgkin's aggressive lymphomas
8. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
9. High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): Final results of a randomized GHSG and EBMT Trial (HD-R1)
10. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation
11. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma
12. Therapy of relapsed or refractory low-grade follicular lymphomas: Factors associated with complete remission, survival and time to treatment failure
13. ESHAP: An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study
14. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
15. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas
16. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease
17. Experience with ifosfamide combinations in malignant lymphomas
18. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and nonHodgkin's lymphoma
19. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: A report on toxicity and efficacy
20. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease
21. Ifosfamide and vinorelbine: An active regimen for patients with relapsed or refractory Hodgkin's disease
22. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma
23. Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma
24. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
25. Report of the Committee on Hodgkin's Disease Staging Classification
26. Toxicity and response criteria of the Eastern Cooperative Oncology Group
27. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
28. Non-parametric estimation from incomplete observations
29. Regression models and life tables
30. A predictive model for aggressive non-Hodgkin's lymphoma
31. Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
32. ICE-an efficient drug combination for stem cell mobilization and high dose treatment of malignant lymphoma
33. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant
34. Rituximab significantly increases the complete rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)